315 related articles for article (PubMed ID: 9754841)
1. The NMDA antagonist model for schizophrenia: promise and pitfalls.
Abi-Saab WM; D'Souza DC; Moghaddam B; Krystal JH
Pharmacopsychiatry; 1998 Jul; 31 Suppl 2():104-9. PubMed ID: 9754841
[TBL] [Abstract][Full Text] [Related]
2. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
[TBL] [Abstract][Full Text] [Related]
3. [Receptor antagonist of NMDA and animal models of schizophrenia].
Bian SZ; Zhang J; Liu WL; Sun ZH; Gu ZL; Jiang XG
Fa Yi Xue Za Zhi; 2009 Dec; 25(6):443-6. PubMed ID: 20225623
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacological modulation of the effects induced by ketamine at subanesthetic doses].
Mechri A; Micallef J; Blin O; Saoud M; Daléry J; Gaha L
Therapie; 2001; 56(5):617-22. PubMed ID: 11806303
[TBL] [Abstract][Full Text] [Related]
5. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
Gouzoulis-Mayfrank E; Heekeren K; Neukirch A; Stoll M; Stock C; Obradovic M; Kovar KA
Pharmacopsychiatry; 2005 Nov; 38(6):301-11. PubMed ID: 16342002
[TBL] [Abstract][Full Text] [Related]
6. The acute effects of NMDA antagonism: from the rodent to the human brain.
Gunduz-Bruce H
Brain Res Rev; 2009 May; 60(2):279-86. PubMed ID: 18703087
[TBL] [Abstract][Full Text] [Related]
7. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors.
Bubeníková-Valesová V; Horácek J; Vrajová M; Höschl C
Neurosci Biobehav Rev; 2008 Jul; 32(5):1014-23. PubMed ID: 18471877
[TBL] [Abstract][Full Text] [Related]
8. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
Large CH
J Psychopharmacol; 2007 May; 21(3):283-301. PubMed ID: 17591656
[TBL] [Abstract][Full Text] [Related]
9. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
10. Does ketamine mimic aspects of schizophrenic speech?
Covington MA; Riedel WJ; Brown C; He C; Morris E; Weinstein S; Semple J; Brown J
J Psychopharmacol; 2007 May; 21(3):338-46. PubMed ID: 17591660
[TBL] [Abstract][Full Text] [Related]
11. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.
Malhotra AK; Pinals DA; Adler CM; Elman I; Clifton A; Pickar D; Breier A
Neuropsychopharmacology; 1997 Sep; 17(3):141-50. PubMed ID: 9272481
[TBL] [Abstract][Full Text] [Related]
12. Effects of age and sex on ketamine-induced hyperactivity in rats.
Wilson C; Kercher M; Quinn B; Murphy A; Fiegel C; McLaurin A
Physiol Behav; 2007 Jun; 91(2-3):202-7. PubMed ID: 17400259
[TBL] [Abstract][Full Text] [Related]
13. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Krystal JH; Karper LP; Seibyl JP; Freeman GK; Delaney R; Bremner JD; Heninger GR; Bowers MB; Charney DS
Arch Gen Psychiatry; 1994 Mar; 51(3):199-214. PubMed ID: 8122957
[TBL] [Abstract][Full Text] [Related]
14. N-methyl-D-aspartate receptor in working memory impairments in schizophrenia: event-related potential study of late stage of working memory process.
Ahn KH; Youn T; Cho SS; Ha TH; Ha KS; Kim MS; Kwon JS
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):993-9. PubMed ID: 14499316
[TBL] [Abstract][Full Text] [Related]
15. The vasodilatory effect of ketamine is independent of the N-methyl-D-aspartate receptor: lack of functional N-methyl-D-aspartate receptors in rat mesenteric artery smooth muscle.
Noh HJ; Bae YM; Park SH; Kim JG; Kim B; Kim YS; Kim SH; Cho SI; Woo NS
Eur J Anaesthesiol; 2009 Aug; 26(8):676-82. PubMed ID: 19352184
[TBL] [Abstract][Full Text] [Related]
16. Effects of NMDA receptor antagonists on visceromotor reflexes and on intestinal motility, in vivo.
Shafton AD; Bogeski G; Kitchener PD; Sanger GJ; Furness JB; Shimizu Y
Neurogastroenterol Motil; 2007 Jul; 19(7):617-24. PubMed ID: 17539896
[TBL] [Abstract][Full Text] [Related]
17. Ketamine modulates theta and gamma oscillations.
Lazarewicz MT; Ehrlichman RS; Maxwell CR; Gandal MJ; Finkel LH; Siegel SJ
J Cogn Neurosci; 2010 Jul; 22(7):1452-64. PubMed ID: 19583475
[TBL] [Abstract][Full Text] [Related]
18. Impact of postnatal blockade of N-methyl-D-aspartate receptors on rat behavior: a search for a new developmental model of schizophrenia.
Wedzony K; Fijal K; Mackowiak M; Chocyk A; Zajaczkowski W
Neuroscience; 2008 Jun; 153(4):1370-9. PubMed ID: 18434025
[TBL] [Abstract][Full Text] [Related]
19. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.
Malhotra AK; Pinals DA; Weingartner H; Sirocco K; Missar CD; Pickar D; Breier A
Neuropsychopharmacology; 1996 May; 14(5):301-7. PubMed ID: 8703299
[TBL] [Abstract][Full Text] [Related]
20. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function.
Krystal JH; Perry EB; Gueorguieva R; Belger A; Madonick SH; Abi-Dargham A; Cooper TB; Macdougall L; Abi-Saab W; D'Souza DC
Arch Gen Psychiatry; 2005 Sep; 62(9):985-94. PubMed ID: 16143730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
